Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) has released its 2021 Cybersecurity Annual Report to inform stakeholders about health care cybersecurity challenges and trends. The report highlights key issues, including cybersecurity risks like phishing and ransomware, and emphasizes the need for collaboration in enhancing security measures across the industry. It introduces best practices for health care providers and outlines upcoming trends such as software-bill-of-materials (SBOM) requirements for 2022. BD aims to integrate cybersecurity throughout its product lifecycle for improved patient care.

BD (Becton, Dickinson and Company) (NYSE: BDX) will release its financial results for Q1 of fiscal year 2022 on February 3, 2022, at 6 a.m. ET. The announcement will include summary financial data for the quarter ending December 31, 2021. Following the release, management will host an audio webcast at 8 a.m. ET to discuss results and operational strategies. For further details and the live audio link, visit www.bd.com/investors. BD is committed to advancing healthcare through innovative technology and solutions.

BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent medical technology leader, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 p.m. Eastern Time. The presentation will be accessible via live webcast on BD's investor relations website, with a replay available afterward. BD focuses on advancing health through technology, diagnostics, and care delivery, supporting healthcare providers and enhancing patient outcomes globally.

BD (Becton, Dickinson and Company) has launched the BD Veritor™ At-Home COVID-19 Test, now available through Everly Health and Southeastern Grocers, including Fresco y Más, Harveys Supermarket, and Winn-Dixie. The test is unique as it utilizes a smartphone app to interpret results, ensuring accuracy without human error. BD emphasizes the test's importance for community safety amidst rising COVID-19 cases, especially during the holiday season. The test is available online and in-store, enabling broad access for consumers.

BD (Becton, Dickinson and Company) announced the formation of a nine-person board of directors for Embecta Corp., which will hold BD's Diabetes Care business after the planned spinoff. The board will be led by David F. Melcher and include notable members such as Claire Pomeroy and Christopher R. Reidy. Devdatt Kurdikar will serve as CEO of Embecta. The spinoff is expected to be completed in Q2 2022, pending regulatory approvals. The governance structure includes various committees, and directors will serve staggered terms.

BD (Becton, Dickinson and Company) has successfully acquired Scanwell Health Inc., a pioneer in smartphone-enabled at-home medical testing. The acquisition aims to enhance BD's digital capabilities for at-home diagnostics, including COVID-19 and other infectious diseases. The BD Veritor™ At-Home COVID-19 Test leverages smartphone technology for accurate result interpretation. Although transaction details were not disclosed, it is anticipated to have an immaterial impact on BD's fiscal 2022 financials. This move underscores BD's commitment to innovative health solutions.

BD (Becton, Dickinson and Company) (NYSE: BDX) has expanded its BD COR™ System with the introduction of the MX instrument, designed for high-throughput molecular testing for infectious diseases, including a new CE-marked assay for sexually transmitted infections. The MX instrument, part of a modular system alongside the PX and GX instruments, can process 1,700 specimens and deliver up to 1,000 results in 24 hours, enhancing laboratory efficiency. The platform automates testing workflows, improving diagnostics for women's health and STIs.

BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.